Russell P. Rother

10.9k total citations · 4 hit papers
72 papers, 7.9k citations indexed

About

Russell P. Rother is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Russell P. Rother has authored 72 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Immunology, 27 papers in Hematology and 21 papers in Genetics. Recurrent topics in Russell P. Rother's work include Complement system in diseases (45 papers), Blood groups and transfusion (21 papers) and Hemoglobinopathies and Related Disorders (17 papers). Russell P. Rother is often cited by papers focused on Complement system in diseases (45 papers), Blood groups and transfusion (21 papers) and Hemoglobinopathies and Related Disorders (17 papers). Russell P. Rother collaborates with scholars based in United States, United Kingdom and Switzerland. Russell P. Rother's co-authors include Peter Hillmen, Leonard Bell, Scott A. Rollins, Mark T. Gladwin, Christopher F. Mojcik, Robert A. Brodsky, Anita Hill, Jörg Schubert, Antonio M. Risitano and Neal S. Young and has published in prestigious journals such as New England Journal of Medicine, Cell and JAMA.

In The Last Decade

Russell P. Rother

72 papers receiving 7.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin

2005 1.2k citations Russell P. Rother, Leonard Bell et al. JAMA profile →
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

2006 878 citations Peter Hillmen, Neal S. Young et al. profile →
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

2016 595 citations Scott A. Rollins, Russell P. Rother et al. profile →
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

2007 570 citations Russell P. Rother, Scott A. Rollins et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Russell P. Rother United States	34	4.7k	2.4k	2.0k	2.0k	989	72	7.9k
Scott A. Rollins United States	38	4.1k 0.9×	1.9k 0.8×	1.4k 0.7×	1.3k 0.7×	1.1k 1.1×	63	7.2k
Robert A. Brodsky United States	62	7.4k 1.6×	5.6k 2.4×	3.2k 1.6×	2.9k 1.4×	1.8k 1.8×	264	13.3k
David Kavanagh United Kingdom	47	5.8k 1.2×	2.3k 1.0×	3.3k 1.6×	902 0.5×	1.1k 1.1×	138	7.9k
Lubka T. Roumenina France	45	5.6k 1.2×	2.0k 0.9×	2.5k 1.2×	979 0.5×	1.5k 1.6×	139	8.1k
Masanori Matsumoto Japan	40	4.5k 1.0×	2.6k 1.1×	1.8k 0.9×	1.4k 0.7×	673 0.7×	308	6.7k
Philippe Lesavre France	38	3.0k 0.6×	1.1k 0.5×	1.9k 0.9×	863 0.4×	1.3k 1.3×	107	6.5k
Leendert A. Trouw Netherlands	55	4.7k 1.0×	1.2k 0.5×	1.1k 0.5×	553 0.3×	1.5k 1.6×	218	9.8k
Otto Götze Germany	46	4.2k 0.9×	1.4k 0.6×	667 0.3×	923 0.5×	1.3k 1.3×	132	6.4k
Karen Vanhoorelbeke Belgium	41	2.8k 0.6×	3.3k 1.4×	822 0.4×	1.1k 0.6×	941 1.0×	210	6.4k
Dominic W. Chung United States	47	2.4k 0.5×	3.2k 1.3×	461 0.2×	1.6k 0.8×	1.7k 1.8×	101	8.1k

Countries citing papers authored by Russell P. Rother

Since Specialization

Citations

This map shows the geographic impact of Russell P. Rother's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Russell P. Rother with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Russell P. Rother more than expected).

Fields of papers citing papers by Russell P. Rother

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Russell P. Rother. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Russell P. Rother. The network helps show where Russell P. Rother may publish in the future.

Co-authorship network of co-authors of Russell P. Rother

This figure shows the co-authorship network connecting the top 25 collaborators of Russell P. Rother. A scholar is included among the top collaborators of Russell P. Rother based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Russell P. Rother. Russell P. Rother is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Hillmen, Peter, Modupe Elebute, Richard J. Kelly, et al.. (2010). Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology. 85(8). 553–559. 140 indexed citations

2.

Hill, Anita, Russell P. Rother, Xunde Wang, et al.. (2010). Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology. 149(3). 414–425. 107 indexed citations

3.

Hill, Anita, Eric Van Den Neste, Petra Muus, et al.. (2008). Improvement in Fatigue With Eculizumab Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria (pnh) Occurs Independent of Changes in Anemia. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 93. 359–359. 3 indexed citations

4.

Rother, Russell P., J. Arp, J. Jiang, et al.. (2008). C5 Blockade with Conventional Immunosuppression Induces Long-Term Graft Survival in Presensitized Recipients. American Journal of Transplantation. 8(6). 1129–1142. 49 indexed citations

5.

Brodsky, Robert A., Neal S. Young, Elisabetta Antonioli, et al.. (2007). Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 111(4). 1840–1847. 457 indexed citations

6.

Zhou, Yuefang, Bendi Gong, Feng Lin, et al.. (2007). Anti-C5 Antibody Treatment Ameliorates Weakness in Experimentally Acquired Myasthenia Gravis. The Journal of Immunology. 179(12). 8562–8567. 70 indexed citations

7.

Wang, Hao, Jacqueline Arp, Weihua Liu, et al.. (2007). Inhibition of Terminal Complement Components in Presensitized Transplant Recipients Prevents Antibody-Mediated Rejection Leading to Long-Term Graft Survival and Accommodation. The Journal of Immunology. 179(7). 4451–4463. 78 indexed citations

8.

Nishimura, Jun‐ichi, Divino Deoliveira, Benny J. Chen, et al.. (2007). Prevention of Graft-Versus-Host Disease in Mouse Model Using Anti-Mouse C5 Antibody.. Blood. 110(11). 3245–3245. 2 indexed citations

9.

Hillmen, Peter, Modupe Elebute, Richard Kelly, et al.. (2007). High Incidence of Progression to Chronic Renal Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).. Blood. 110(11). 3678–3678. 13 indexed citations

10.

Hill, Anita, Peter Hillmen, Stephen J. Richards, et al.. (2005). Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 106(7). 2559–2565. 165 indexed citations

11.

Tacken, Paul J., I. Jolanda M. de Vries, Karlijn Gijzen, et al.. (2005). Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti–DC-SIGN antibody. Blood. 106(4). 1278–1285. 219 indexed citations

12.

Wang, Hao, Jifu Jiang, Weihua Liu, et al.. (2005). Prevention of Acute Vascular Rejection by a Functionally Blocking Anti-C5 Monoclonal Antibody Combined with Cyclosporine. Transplantation. 79(9). 1121–1127. 42 indexed citations

13.

Rother, Russell P., Leonard Bell, Peter Hillmen, & Mark T. Gladwin. (2005). The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin. JAMA. 293(13). 1653–1653. 1179 indexed citations breakdown →

14.

Subudhi, Sumit K., Russell P. Rother, Susan J. Faas, et al.. (2001). Inducible Costimulator Regulates Th2-Mediated Inflammation, but Not Th2 Differentiation, in a Model of Allergic Airway Disease. The Journal of Immunology. 167(4). 1996–2003. 107 indexed citations

15.

Faas, Susan J., Deborah J. Reed, Dayang Wu, et al.. (2000). Primary Structure and Functional Characterization of a Soluble, Alternatively Spliced Form of B7-1. The Journal of Immunology. 164(12). 6340–6348. 43 indexed citations

16.

Rother, Russell P. & Uri Galili. (1999). α-Gal Epitopes on Viral Glycoproteins. PubMed. 32. 143–172. 4 indexed citations

17.

Rollins, Scott A., Carl Birks, E Setter, Stephen P. Squinto, & Russell P. Rother. (1996). Retroviral Vector Producer Cell Killing in Human Serum Is Mediated by Natural Antibody and Complement: Strategies for Evading the Humoral Immune Response. Human Gene Therapy. 7(5). 619–626. 24 indexed citations

18.

Mueller, John P., Mark J. Evans, Roxanne Cofiell, et al.. (1995). PORCINE VASCULAR CELL ADHESION MOLECULE (VCAM) MEDIATES ENDOTHELIAL CELL ADHESION TO HUMAN T CELLS. Transplantation. 60(11). 1299–1305. 27 indexed citations

19.

Mueller, John P., Mark J. Evans, Roxanne Cofiell, et al.. (1995). PORCINE VASCULAR CELL ADHESION MOLECULE (VCAM) MEDIATES ENDOTHELIAL CELL ADHESION TO HUMAN T CELLS. Transplantation. 60(11). 1299–1305. 24 indexed citations

20.

Rother, Russell P., Mark Barton Frank, & Patricia S. Thomas. (1992). Purification, primary structure, bacterial expression and subcellular distribution of an oocyte‐specific protein in Xenopus. European Journal of Biochemistry. 206(3). 673–683. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact